BCDA Historical PE Ratio Notes

— BioCardia, Inc. (ticker symbol: BCDA) is a clinical-stage regenerative medicine company focused primarily on developing innovative therapies for cardiovascular diseases, particularly through cell-based approaches to treat heart failure and other heart conditions. The company's flagship product candidates, including CardiAMP™ and CardiALLO™, are designed to improve outcomes for patients with chronic cardiac diseases, aiming to bring to market new minimally invasive therapies that address large unmet needs. For investors examining BioCardia's historical PE ratio data, it's essential to understand that as a clinical-stage biotech, BCDA typically generates minimal, if any, recurring revenue and often reports operating losses rather than consistent profits while its therapies are still in development and pre-approval stages. This means the historical PE ratio for BCDA may either be negative or not meaningful for many periods — a reflection of ongoing R&D spending without offsetting earnings. Investors should interpret the company's PE trends in the context of its development milestones, funding rounds, or FDA-related progress, as anticipation of future therapy approvals and commercialization can cause significant volatility in both share price & forward-looking earnings expectations, sharply impacting reported PE ratios on charts and tables.

On this page we presented the BCDA Historical PE Ratio information for BioCardia' stock. The average BCDA historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average BCDA historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this BCDA historical PE result, against the recent PE: when this page was posted on 8/17/2026, the most recent closing price for BCDA had been 0.94, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on BCDA or any other given stock, valuation analysis for BCDA can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate BioCardia PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for BCDA. Thanks for visiting, and the next time you need to research BCDA Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.